Nuwellis shares are trading higher after the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to its pediatric CRRT device branded Vivian.
Portfolio Pulse from Benzinga Newsdesk
Nuwellis shares surged following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application concerning its pediatric CRRT device, Vivian.

May 02, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuwellis has received a Notice of Allowance for a patent on its pediatric CRRT device, Vivian, indicating a positive development in its product pipeline.
The receipt of a Notice of Allowance for a patent application is a critical regulatory milestone that can enhance the company's intellectual property portfolio, potentially leading to increased investor confidence and market competitiveness. This development is particularly significant for Nuwellis as it pertains directly to one of their products, indicating a positive impact on the company's future revenue streams and growth prospects in the pediatric healthcare market.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100